Alltech and ProGnosis Biotech will collaborate to advance mycotoxin-testing capabilities

As mycotoxin risks continue to evolve across regions worldwide, producers and feed manufacturers need access to both rapid testing technologies and localized intelligence to make informed decisions. The collaboration between Alltech and ProGnosis is designed to strengthen mycotoxin monitoring and risk-management capabilities while delivering actionable insights that support the industry globally.

Agriculture continues to face increasing pressure from changing weather patterns, as periods of drought, heat stress and excessive rainfall influence crop quality and create conditions that favor mycotoxin development.

While the alliance between Alltech and ProGnosis has a global scope, Europe, the Middle East and Africa (EMEA) will be the primary focus of the initial phase, given the region's growing mycotoxin challenges and the opportunity to harness the complementary strengths of Alltech and ProGnosis.

"Alltech RAPIREAD allows users to understand their true mycotoxin risk as it relates to animal performance and health," said Dr. Alexandra Weaver, global technical support for Alltech. "The collaboration between Alltech and ProGnosis gives those in the agricultural industry the ability to not only test for mycotoxins but also gain insights about their data."

"ProGnosis Biotech is dedicated to the development of fast and simple testing solutions to ensure food safety throughout the supply chain," said Sebastien Poisson, business development manager at ProGnosis. "Integrating ProGnosis Biotech's rapid lateral flow test strips into Alltech's RAPIREAD platform seamlessly fuses ProGnosis' readers with Alltech's global risk-management platform, combining rapid testing with automated trend and risk analysis."

For more information, visit knowmycotoxins.com/mycotoxin-detection/alltech-rapiread.